{'fraction_non_alphanumeric': 0.023132848645076007, 'fraction_numerical': 0.0039656311962987445, 'mean_word_length': 4.778625954198473, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Double PEGylation Significantly Improves Pharmacokinetic Properties of Irinotecan Containing Nanoparticles in a Zebrafish Model



Plasma pharmacokinetic (PK) properties of oral or injectable
drugs dictate whether the drug is clinically viable or not. Poor PK properties often result in
termination of the development of the drug. Optimizing PK properties of drugs is a major
challenge in the pharmaceutical industry. Ideally, sufficient circulating time of the drug in
the plasma is required, so that it has adequate opportunity to reach the target tissue.



We have used irinotecan, a known drug with poor PK properties, as a prototype
to apply our idea of improving PK in plasma by PEGylation. We compared the PK profile
of free irinotecan, irinotecan packaged in nanoparticles (NPs) with single polyethylene
glycol (PEG) layer and irinotecan packaged in NPs with double PEG layer. PK properties
of these formulations were compared in a zebrafish model when given intraperitoneally.



Dramatic differences in the PK properties of the three formulations were observed.
The AUC, Cmax and T1/2 of irinotecan in each of these formulations differed from
each other significantly. Approx. 4.5 - fold higher peak concentration (Cmax) and ~3 - fold
higher exposure (AUC0-t) were observed for double PEGylated NPs as compared to free
irinotecan and single PEGylated NPs.



In summary, our data suggest that double PEGylation of NPs could be a very
effective way to improve PK properties of drugs such as irinotecan.
